Novartis Poland sp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-10-31
Share capital
44,183,000.00 PLN
Activity description

Novartis Poland is part of a global healthcare company that works with patients, caregivers and healthcare professionals to improve and extend human life. The company supports knowledge exchange, education and therapy development, while pursuing environmental and social responsibility and building a diverse team serving more than 766 million patients worldwide.

Registered address
Marynarska 15, 02-674 Warszawa, Poland
Social media
Electronic delivery address
AE:PL-57849-90025-BVIHT-28

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$3,001,733

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 69 days for 2021). All were audited by a statutory auditor.

  • 202525/08/2026
  • 202403/07/2025
  • 202305/07/2024
  • 202212/07/2023
  • 202122/09/2022
  • 202006/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods17 / 1,138
Top 1.5%
Division · Wholesale trade67 / 20,115
Top <1%
City · Warszawa172 / 56,955
Top <1%
Voivodeship · Mazowieckie208 / 77,195
Top <1%
Country · Poland515 / 298,026
Top <1%

Results vs industry

Revenue
This companyUSD 378.15mMedianUSD 1.08mAverageUSD 22.29m
Net profit
This companyUSD 11.86mMedianUSD 38.88kAverageUSD 876.69k
Operating costs
This companyUSD 358.81mMedianUSD 962.19kAverageUSD 20.97m
Assets
This companyUSD 248.32mMedianUSD 609.97kAverageUSD 11.79m

News

Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term

Ad hoc announcement pursuant to Art. 53 LR

Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS

Basel, November 18, 2026 – Novartis will present data from nearly 60 abstracts at the 2026 San Antonio Breast Cancer Symposium (SABCS) and 68ᵗʰ American Society of Hematology (ASH) Annual Meeting & Exposition. Together, the data reinforce Novartis leadership in breast cancer and hematology, spanning approved medicines and a promising pipeline of next-generation therapies.

Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Basel, November 17, 2026 – Novartis today announced that the US Food and Drug Administration (FDA) approved Cosentyx® (secukinumab) 150 mg for the treatment of adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.¹ Cosentyx is the first and only anti-interleukin-17 (anti-IL-17) biologic approved for people living with PMR, a common inflammatory disease that primarily affects adults over 50, providing…

Novartis receives positive CHMP opinion for Cosentyx® in adolescents aged 12+ with hidradenitis suppurativa (HS)

Basel, November 13, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization of Cosentyx ® (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa (HS) who have had an inadequate response to conventional systemic HS therapy. 6 If approved by the European Commission (EC), Cosentyx would become the…

New long-term Rhapsido® (remibrutinib) Phase III data show sustained efficacy through week 52 in chronic inducible urticaria (CIndU)

Basel, November 12, 2026 – Novartis today announced 52-week results from the Phase III RemIND program evaluating Rhapsido ® (remibrutinib) in chronic inducible urticaria (CIndU). In the long-term analysis from the RemIND study, Rhapsido 25 mg twice daily showed early and sustained efficacy through Week 52 in patients across the three most prevalent CIndU subtypes: symptomatic dermographism (SD), cold urticaria (ColdU) and cholinergic urticaria (CholU). 1 The data will be presented as a…

Novartis ranks first place in 2026 Access to Medicine Index

Basel, November 10, 2026 – Novartis today announced the company has ranked first place in the 2026 Access to Medicine Index. Published every two years, the Index is an independent assessment of how major research-based pharmaceutical companies are improving access to medicines. “Being ranked first in the Access to Medicine Index for the second consecutive time is an honor, and a recognition of our continued efforts to expand access to healthcare together with our partners,” said Vas Narasimhan…

Industry

Offer

Websites

The company has 5 websites, including 2 versions for foreign markets (e.g. China, Russia). Most of them run on Drupal. The sites are available in: English, Russian and Chinese.

Public procurement

13 tenders recorded as contractor, with a total value of $34,796,045.

SubjectAmount
Supply of medicinal products, pharmaceutical preparations, medical devices and other products
$3.7M
Supply of medicinal products for drug programmes as part of CAR-T therapy
$1.7M
Supply of medicines, pharmaceutical preparations, oncology medicines, medical devices, dressings, sutures, contrast agents and other items.
$2.6M

Trademarks

The company currently holds no active trademarks with the Polish Patent Office. 3 marks have expired or were not registered. The first mark was filed in 2009.

MarkNumberClassesStatusProtected until
ZROZUM LEPIEJ SWOJĄ MIGRENĘ Z EXCEDRIN MIGRASTOP Z.4305449, 16, 35, 41Not registered –
DiabetoNews (word)Z.40634135, 41Expired –
KOJĄCY DOTYK (word)Z.3537663, 5Expired –
MarkProtected until
ZROZUM LEPIEJ SWOJĄ MIGRENĘ Z EXCEDRIN MIGRASTOP –
DiabetoNews (word)–
KOJĄCY DOTYK (word)–

Job offers

The company has its own careers page: novartis.com/careers.

Authorized Representatives

Jolanta Anna Chlebicka-Dominiak age 53 – Attorney-in-fact (sole)
Carlos Eid – Management Board Member
Emiliano Zavagli age 37 – Management Board Member
Yu Tian – President of the Management Board

Manner of representation

The following are authorized to submit declarations of will within the scope of rights and obligations and to sign documents on behalf of the company: each member of the management board independently or an individual commercial proxy independently.

Ownership

OwnerSharesShare valueStake
Novartis Pharma Ag
44,183$11,934,900.05100%

Beneficial owners

Person

Capital group

The company belongs to the Novartis AG (Switzerland) group. Its direct owner is Novartis Pharma AG (Switzerland). The group has 17 companies, 15 of them abroad.

NameCountry
Alcon Ophthalmika GmbHAustria
EBEWE Pharma Ges.m.b.H. Nfg.KGAustria
Evonile Pharma LimitedIndia
Novartis Bioventures AGSwitzerland
Novartis Capital CorporationUnited States

Sanctions and PEP

Sanctions

No matches (EU, UN, US, UK, MSWiA, World Bank)

PEP

No matches

Bank accounts

Registered as a VAT taxpayer on 1993-07-05.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 1.6M

MSiG notices

Publication dateEvent
Apr 22, 2025Merger registered

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Novo Nordisk Pharmaceutical Services sp. z o.o.
MSD Polska Dystrybucja sp. z o.o.
Janssen-Cilag Polska sp. z o.o.
Bristol-Myers Squibb Polska sp. z o.o.
Astellas Pharma sp. z o.o.
Accord Healthcare Polska sp. z o.o.
Gilead Sciences Poland sp. z o.o.
Amgen sp. z o.o.
Pfizer Polska sp. z o.o.
Ipsen Poland sp. z o.o.

Change history

DateEvent
2010-12-20Address change
2004-02-16Share capital increase
2001-10-31Entered in the register

FAQ

Last updated: 2026-10-02